Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An Experimental Study That Investigate Effects of Atreleuton in Metabolic Syndrome

Autor: Sertaç Ayhan, Tevfik Noyan

Publikováno v: Eastern Journal Of Medicine. 26:280-285

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b33c65ea1158b576de4533fd5b604dc2
https://doi.org/10.5505/ejm.2021.65477

Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study

Autor: Jean-Claude Tardif, Reda Ibrahim, Josephine Pressacco, Jean Grégoire, Suguru Matsumoto, Philippe L. L’Allier, Matthew J. Budoff

Publikováno v: Clinical cardiology, vol 40, iss 4
Matsumoto, S; Ibrahim, R; Gregoire, JC; L'Allier, PL; Pressacco, J; Tardif, J-C; et al.(2017). Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. CLINICAL CARDIOLOGY, 40(4), 210-215. doi: 10.1002/clc.22646. UCLA: Retrieved from: http://www.escholarship.org/uc/item/9f65w0rm

BACKGROUND: Inflammation has a key role in the process of atherosclerosis. Production of leukotrienes by 5‐lipoxygenase has been linked to atherosclerotic plaques and cardiovascular events. HYPOTHESIS: In this study, a selective 5‐LO inhibitor wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b905c4848b89eded3727fb39ed8b05
https://escholarship.org/uc/item/9f65w0rm

Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome

Autor: Anna Nozza, Philippe L. L’Allier, Reda Ibrahim, Tilmann M. Brotz, Simon Kouz, Josephine Pressacco, Marc-André Lavoie, Rebecca Taub, Jean-Claude Tardif, Janie Paquin, Jean Grégoire, Mariève Cossette

Publikováno v: Circulation: Cardiovascular Imaging. 3:298-307

Background—Production of leukotrienes by 5-lipoxygenase (5-LO) has been linked to unstable atherosclerotic plaques and cardiovascular events. VIA-2291 is a potent 5-LO inhibitor.Methods and Results—In a double-blinded study, 191 patients were ran

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1835ebe554ff1aa322b70ecd8ff4271
https://doi.org/10.1161/circimaging.110.937169

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.